Practice
Featured experience
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Azul $800 million secured notes offering
The senior secured notes are due 2028
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
NBCUniversal partnership with MultiChoice to relaunch Showmax using Peacock
We are advising NBCUniversal on the transaction to relaunch MultiChoice’s Showmax service using the Peacock platform
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of…
Beam Therapeutics $180 million IPO
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common…
1Life Healthcare $282 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the …
Black Diamond Therapeutics $231.3 million IPO
Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares…
I-Mab $103.7 million IPO and Nasdaq listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary…
Equinix acquisition of Packet Host
Davis Polk is advising Equinix, Inc. in connection with its acquisition of Packet Host Inc., the leading bare metal…
Tencent and Tencent Music strategic investment in Universal Music Group
Davis Polk is advising Tencent Holdings Limited (“Tencent”) and Tencent Music Entertainment Group (“Tencent Music”) on the…
Pivotal Software merger with VMware
Davis Polk advised Pivotal Software, Inc. in connection with its merger with VMware, Inc. Pursuant to the merger, holders of…
Bertelsmann acquisition of full ownership of Penguin Random House
Davis Polk is advising Bertelsmann SE & Co. KGaA on its $675 million acquisition of the stake it did not hold in Penguin…
Davis Polk Advises Charles River on Its Acquisition of HemaCare
Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of…